Last reviewed · How we verify
Radium-223 and enzalutamide
At a glance
| Generic name | Radium-223 and enzalutamide |
|---|---|
| Sponsor | Cancer Trials Ireland |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) (PHASE4)
- Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer (PHASE2)
- Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Phase III Radium 223 mCRPC-PEACE III (PHASE3)
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (PHASE3)
- Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status (PHASE2)
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radium-223 and enzalutamide CI brief — competitive landscape report
- Radium-223 and enzalutamide updates RSS · CI watch RSS
- Cancer Trials Ireland portfolio CI